Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 234-238

  Cugno, Massimo ^a   Cicardi, Marco ^a   Colucci, Mario ^b   Bisiani, Giuliana ^a   Merlini, Piera Angelica ^c   Spinola, Alessandra ^c   Paonessa, Raffaella ^a   Agostoni, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIBODY; IMMUNOGLOBULIN G; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL;

EID: 0029819712     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650560     Document Type: Article

References (20)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
2. Lijnen HR, Collen D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3: 67-77.
3. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activators, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
4. ISIS-3 Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
5. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329: 703-8.
6. Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM Junior, Glaesle-Schwarz L, Grosbard EB. Low incidence of antibodies to recombinant human tissue type plasminogen activator in treated patients. Thromb Haemost 1990; 64: 276-80.
7. Fineberg SL, Galloway JA, Fineberg NS, Rathbun MJ, Huffed S. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983; 25: 465-9.
8. Gribben JG, Devereux S, Thomas MSB, Keim M, Jones HM, Goldstone AH, Linch DC. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335: 434-7.
9. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant-alfa-2b interferon (Intron A). Am J Med 1986; 80: 223-8.
10. Berzofsky JA, Bercower IJ, Epstein SL. Antigen-antibody interaction and monoclonal antibodies. In: Fundamental Immunology. Paul WE, ed. New York: Raven Press, 1975: 151-9.
11. Colucci M, Cavallo LG, Agnelli G, Mele A, Burgi R, Heim J, Semeraro N. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Thromb Haemost 1993; 69: 466-72.
12. Haverkate F, Brakman P. Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC, eds. New York: Raven Press, 1975: 151-9.
13. Lawson JH, Pennel BJ, Olson JD, Mann KJ. Isolation and characterization of an acquired anti-thrombin antibody. Blood 1990; 76: 2249-57.
14. Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with lupus anticoagulant. Thromb Haemost 1992; 67: 507-9.
15. D'Angelo A, Della Valle P, Crippa L, Pattarini E, Grimaldi LME, Viganò D'Angelo S. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328: 1753-7.
16. Cicardi M, Bisiani G, Cugno M, Späth P, Agostoni A. Autoimmune C1-inhibitor deficiency: report of eight patients. Am J Med 1993; 95: 169-75.
17. Varela F, Andersson Å, Dietrich G, Sundblad A, Olmberg D, Kazatchkine M, Coutinho A. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991; 88: 5917-21.
18. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Veharn GA, Ward CA, Bennet WF, Yelverton E, Seeburg PA, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. Coli. Nature 1983; 301: 214-21.
19. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-41.
20. Ruiz-Arguelles A, Angles-Cano E, Perez-Romano B, Ruiz-Arguelles G, Deleze M, Alarcon-Segovia D, Gaussem P. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am J Hematol 1995; 49: 109-14.